Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Jul 8;58(10):2355–2364. doi: 10.2337/db09-0432

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 7. — Effect of 3 weeks of LY333531 (LY) (1 mg/kg/day) or L-NIL (3 mg/kg/day) treatment on hemodynamic parameters in freely moving conscious rats. Data represent means ± SE (n = 8). A: Effect of LY333531 or L-NIL on MABP. *P < 0.05 compared with all other groups. B: Effect of LY333531 or L-NIL on heart rate. *P < 0.05 compared with all other groups. C: Effect of LY333531 or L-NIL on endothelial function as measured by the change in blood pressure (ΔMABP) in response to a single intravenous bolus dose of l-NAME (10 mg/kg) in control (C) and diabetic (D) rats. *P < 0.05 compared with their respective control groups. #P < 0.05 compared with diabetic and diabetic + LY333531 groups. D: Effect of LY333531 or L-NIL on pressor responses to bolus doses of methoxamine (100–300 nmoles/kg). *P < 0.05 compared with all other groups; #P < 0.05 compared with diabetic rats.